0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Enzyme-Linked Immunosorbent Assay of Antibodies to Epstein-Barr Virus Nuclear and Early Antigens in Patients with Infectious Mononucleosis and Nasopharyngeal Carcinoma

JESSICA HALPRIN, M.S.; ALAN L. SCOTT, Ph.D.; LISA JACOBSON, M.S.; PAUL H. LEVINE, M.D.; J. H. C. HO, M.D.; JAMES C. NIEDERMAN, M.D.; S. DIANE HAYWARD, Ph.D.; and GREGORY MILMAN, Ph.D.
[+] Article and Author Information

Grant support: by grants ES03131 and GM 32950 (Dr. Milman) by the National Institute of Environmental Health Sciences and the National Institute of General Medical Sciences; grant AI22775 (Dr. Scott) by the National Institute of Allergy and Infectious Diseases; and grant CA37314 (Dr. Hayward) by the National Cancer Institute.

▸Requests for reprints should be addressed to Gregory Milman, Ph.D.; Department of Biochemistry, The Johns Hopkins University, School of Hygiene and Public Health, 615 North Wolfe Street; Baltimore, MD 21205.


Baltimore and Bethesda, Maryland; Kowloon, Hong Kong; and New Haven, Connecticut


© 1986 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1986;104(3):331-337. doi:10.7326/0003-4819-104-3-331
Text Size: A A A

A sensitive enzyme-linked immunosorbent assay was used to measure titers of IgG antibodies against bacterially synthesized Epstein-Barr virus nuclear antigen and early antigen in sera from 100 healthy North Americans, 40 North American patients with infectious mononucleosis, and 48 Asian patients with nasopharyngeal carcinoma. All healthy persons previously infected with Epstein-Barr virus had antibodies to nuclear antigen, and 70% had very low but detectable antibody titers to early antigen. In contrast, patients with mononucleosis had nondetectable or very low levels of antibodies to nuclear antigen and high antibody levels to early antigen. High levels of antibody to early antigen also were seen in patients with nasopharyngeal carcinoma, and a decrease in this response during the first 12 months after diagnosis and treatment was a significant prognostic indicator of survival. The probability of survival was 75% for patients whose antibody concentration to early antigen remained constant or decreased, and near 0% for patients with increasing levels of antibody.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)